Page last updated: 2024-11-06

nicotinuric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nicotinuric acid, also known as N-nicotinoyl-glycine, is a naturally occurring compound formed in the human body as a metabolite of nicotine. It is produced by the conjugation of nicotinic acid with glycine, a process catalyzed by the enzyme nicotinic acid N-methyltransferase. Nicotinuric acid is excreted in the urine and is thought to play a role in detoxification of nicotine. Research suggests that nicotinuric acid may be a potential biomarker for tobacco use. The compound is studied to understand its role in nicotine metabolism and its potential use as a biomarker for tobacco use. Additionally, its synthesis and metabolic pathways are explored to gain insights into the detoxification processes in the body.'

nicotinuric acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-nicotinoylglycine : An N-acylglycine having nicotinoyl as the acyl substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID68499
CHEMBL ID458725
CHEBI ID7563
SCHEMBL ID351962
MeSH IDM0043075

Synonyms (56)

Synonym
nicotinoylglycine
glycine, n-nicotinoyl-
nsc-71273
glycine, n-(3-pyridinylcarbonyl)-
nsc71273
OPREA1_707292
583-08-4
nicotinuric acid
C05380
nicotinylglycine
nicotinurate
n-(pyridin-3-ylcarbonyl)glycine
CHEBI:7563 ,
n-nicotinoylglycine
n-nicotinylglycine
A346B81A-6C0D-4148-8571-4C4A8C9B5974
2-(pyridine-3-carbonylamino)acetic acid
BMSE000708
N0092
CHEMBL458725
n-nicotinoyl-glycine
AKOS000133441
STL124046
77v5315piu ,
unii-77v5315piu
nsc 71273
einecs 209-497-0
S3322
FT-0672725
FT-0632437
2-[(3-pyridinylcarbonyl)amino]acetic acid
2-(nicotinylamino)acetic acid
(nicotinoylamino)acetic acid
SCHEMBL351962
BBL027892
[(3-pyridinylcarbonyl)amino]acetic acid #
nicotinoyl-glycine
2-(nicotinamido)acetic acid
mfcd00023578
DTXSID50207022
2-(pyridin-3-ylformamido)acetic acid
n-(3-pyridinylcarbonyl)-glycine
n-nicotinuric acid
n-nicotinurate
n-(3-pyridinylcarbonyl)-(9ci)-glycine
n-nicotinoyl-(8ci)-glycine
AS-59081
2-[(pyridin-3-yl)formamido]acetic acid
CS-0062277
HY-113353
SY041590
F19167
Q27107528
EN300-107990
A869480
Z239129822

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Dose recommendations for these patients are not available because pharmacokinetic data are missing."( Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients.
Bode-Böger, SM; Luley, C; Martens-Lobenhoffer, J; Reiche, I; Tröger, U; Westphal, S, 2011
)
0.37
"Ten dialysis patients and eight patients with CKD were enrolled in a prospective, three-period, open-label pharmacokinetic study."( Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients.
Bode-Böger, SM; Luley, C; Martens-Lobenhoffer, J; Reiche, I; Tröger, U; Westphal, S, 2011
)
0.37
" The method was sensitive, specific, precise, accurate and suitable for bioequivalence and pharmacokinetic studies."( Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Damaramadugu, R; Inamadugu, JK; Mullangi, R; Ponneri, V, 2010
)
0.59
"This was an open-label, randomized, three-period, multiple-dose crossover study that assessed the potential for pharmacokinetic interaction between extended-release niacin and ezetimibe/simvastatin and their major metabolites."( Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects.
Cutler, DL; Kim, KT; Kosoglou, T; Statkevich, P; Taggart, W; Triantafyllou, I; Xuan, F; Zhu, Y, 2011
)
0.37
"There is a small pharmacokinetic drug interaction between ER niacin and ezetimibe/simvastatin and although this is not considered to be clinically significant, the concomitant use of these drugs should be appropriately monitored, especially during the niacin titration period."( Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects.
Cutler, DL; Kim, KT; Kosoglou, T; Statkevich, P; Taggart, W; Triantafyllou, I; Xuan, F; Zhu, Y, 2011
)
0.37

Compound-Compound Interactions

ExcerptReferenceRelevance
" The method is based on solid phase extraction in combination with ion-paired reversed phase high performance liquid chromatography."( Simultaneous determination of nicotinic acid and its two metabolites in human plasma using solid-phase extraction in combination with high performance liquid chromatography.
Miyauchi, Y; Nakamura, T; Sano, N, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
" Since both drugs are extensively metabolized, this study investigated the bioavailability and pharmacokinetics of their co-administration following single-dose administration."( The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.
Cefali, E; Menon, R; Tolbert, D, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" Twelve healthy males were enrolled in an open-label, dose-rate escalation study and received 2000 mg niacin at 3 different dosing rates."( Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites.
Adams, MH; Cefali, EA; González, MA; Leu, JH; Menon, RM; Tolbert, DS, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
N-acylglycineAn N-acyl-amino acid in which amino acid specified is glycine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID388272Activity of rat recombinant peptidylglycine alpha-amidating monooxygenase assessed as stimulation of oxygen consumption2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID1289654Drug level in Sprague-Dawley rat intestine treated with N-(2-((5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenamido)ethyl)-nicotinamide at 300 mg/kg, qd administered through oral gavage for 7 days measured 2 hrs post last dose by LC/MS/MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID388273Ratio of Vm(app) to Km(app) for rat recombinant peptidylglycine alpha-amidating monooxygenase2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID1289652Drug level in Sprague-Dawley rat plasma treated with N-(2-((5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenamido)ethyl)-nicotinamide at 300 mg/kg, qd administered through oral gavage for 7 days measured 2 hrs post last dose by LC/MS/MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID1289653Drug level in Sprague-Dawley rat liver treated with N-(2-((5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenamido)ethyl)-nicotinamide at 300 mg/kg, qd administered through oral gavage for 7 days measured 2 hrs post last dose by LC/MS/MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID388274Ratio of Vm(app) to Km(app) for rat recombinant peptidylglycine alpha-amidating monooxygenase relative to hippuric acid2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (28.95)18.7374
1990's6 (15.79)18.2507
2000's7 (18.42)29.6817
2010's13 (34.21)24.3611
2020's1 (2.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.49 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (18.42%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (81.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]